Last updated: July 27, 2026
Fresenius Kabi USA, LLC v. Dr. Reddy’s Laboratories, Inc. (1:16-cv-03316): Litigation Summary, Patent Assertions, and Commercial Risk
Fresenius Kabi USA, LLC brought a patent infringement suit against Dr. Reddy’s Laboratories, Inc. under case number 1:16-cv-03316. The action is tracked as a US federal Hatch-Waxman patent dispute, with typical exposure tied to Orange Book-listed patents and potential generic or “H-F” product entry. A complete, accurate litigation summary requires case docket access (complaint, asserted patent list, claim charts, claim construction orders, and any settlement or final judgment), which is not provided here.
Because the record is not included, providing a “hard data” litigation summary (asserted patents, parties’ positions, procedural milestones, and outcomes) would risk inaccuracy.
What is Fresenius Kabi USA, LLC v. Dr. Reddy’s Laboratories, Inc. 1:16-cv-03316 about?
No reliable case content is available in the prompt. A litigation summary at the precision level expected for R&D, licensing, and litigation decisions must enumerate at minimum: asserted US patents, the accused product(s) and dosage forms, filing basis (Paragraph IV, non-infringement, invalidity), forum (district and judge), and the procedural posture (dismissal, claim construction, summary judgment, trial, or settlement).
What patents were asserted in 1:16-cv-03316?
Not available in the prompt.
Which Fresenius Kabi product(s) were accused?
Not available in the prompt.
What was the litigation posture as of 2016?
Not available in the prompt.
Which claims and legal theories were typically used in this Hatch-Waxman case?
No complaint or order text is provided. A correct analysis must tie legal theories to specific asserted patents and the mechanism of infringement alleged (direct, induced, or contributory), plus any invalidity grounds (35 USC 101, 102, 103, 112), and whether defenses were addressed via claim construction.
Did Fresenius Kabi plead direct infringement only?
Not available.
Did Dr. Reddy’s challenge infringement and/or validity?
Not available.
Was there any Section 101 / obviousness / enablement attack?
Not available.
What did the docket show for 1:16-cv-03316: key dates, rulings, and milestones?
No docket milestones are included in the prompt. A proper timeline should list service dates, responsive pleadings, motion practice (MTE, TRO/PI if any, claim construction), summary judgment, trial dates, and final judgment or stipulated dismissal with settlement terms if disclosed.
When were the complaint and answer filed?
Not available.
Were there claim construction orders?
Not available.
Was there summary judgment or trial?
Not available.
Did the case settle, and what was the likely entry impact?
Settlement terms are not provided. For Hatch-Waxman disputes, the business impact usually hinges on: whether there was a consent judgment, agreed launch date, “carve-out” design changes, and whether exclusivity was extended or generic entry was delayed by a particular number of days or until a specific expiration date.
Were there any stipulated dismissals or consent judgments?
Not available.
What launch date (if any) was agreed?
Not available.
How strong is the patent estate at issue in 1:16-cv-03316?
Patent strength analysis must be grounded in: the asserted claims, prosecution histories, claim construction outcomes, and any validity findings. Without asserted patent numbers and court rulings, a strength assessment would be speculative.
What is the expiration profile of the asserted patents?
Not available.
Did any asserted claims survive dispositive motions?
Not available.
Did the court narrow the scope via claim construction?
Not available.
What Orange Book status matters for Fresenius Kabi’s asserted patents?
Orange Book status must be mapped to the specific product and NDA/BLA number. The prompt does not identify the drug product, NDA number, or Orange Book listing. Without those, a correct “Orange Book status” section cannot be produced.
Is the asserted patent listed as an “expiration” or “exclusivity” patent?
Not available.
What is the Orange Book expiration timeline for the listed patents?
Not available.
What generic entry risks exist for Dr. Reddy’s after this litigation?
Entry risk depends on what patents were found infringed/valid, which claims were held invalid or not infringed, and whether any injunction or launch restriction remained. Without outcomes, the risk profile cannot be quantified.
Risk if the court found infringement
Not available.
Risk if the court found invalidity
Not available.
Risk if the case ended by settlement
Not available.
How does Dr. Reddy’s strategy in this case compare with other Hatch-Waxman litigations?
Comparison requires: the asserted patent portfolio, the accused product’s formulation/label, and the procedural outcomes. No case record is present.
Did Dr. Reddy’s file multiple Paragraph IV litigations around the same time?
Not available.
Did other companies face similar assertions from Fresenius Kabi?
Not available.
Which courts and judges handled this matter, and what does that mean for outcomes?
A court/judge analysis must cite the district, the judge, and any relevant scheduling or ruling patterns tied to the record. The prompt does not specify jurisdiction or judge.
What district court is case 1:16-cv-03316 in?
Not available.
What judge was assigned?
Not available.
Key Takeaways
- A litigation summary for Fresenius Kabi USA, LLC v. Dr. Reddy’s Laboratories, Inc. (1:16-cv-03316) requires docket and filing details (asserted patents, accused product, procedural milestones, and final disposition). None are included in the prompt.
- Without those specifics, any statement about asserted patents, legal theories, rulings, or settlement terms would not meet the accuracy standard for patent-and-litigation decision-making.
FAQs
- What is the district and judge for Fresenius Kabi USA, LLC v. Dr. Reddy’s Laboratories, Inc. (1:16-cv-03316)?
- Which US patents did Fresenius Kabi assert in case 1:16-cv-03316?
- What Paragraph IV arguments did Dr. Reddy’s raise in 1:16-cv-03316?
- Did the court issue claim construction or summary judgment orders in 1:16-cv-03316?
- Did the parties settle, and what entry timing resulted from the disposition of 1:16-cv-03316?
References (APA)
- United States District Court. Fresenius Kabi USA, LLC v. Dr. Reddy’s Laboratories, Inc., No. 1:16-cv-03316. (Case docket and filings not provided in prompt.)
